Day: June 5, 2024

Colorado Ford Dealers Secure Naming Rights to New Outdoor Amphitheater in Colorado Springs, Colorado

“Ford Amphitheater” will be the most luxurious amphitheater in the Nation Ten-year term struck between Notes Live, Inc. dba Venu Holding Corporation, and Ford CHARLOTTE, N.C., June 05, 2024 (GLOBE NEWSWIRE) — Fresh Vine Wine Inc. (NYSE American: VINE) (“Fresh Vine”) today announced that its merger partner live entertainment and hospitality company formally Notes Live, Inc. dba Venu Holding Corporation (“VENU”) struck a ten-year naming rights term with Colorado Ford Dealers to the new outdoor amphitheater in Colorado Springs, Colorado. On June 4, 2024 — Ford (NYSE: F) has acquired the naming rights to the ultra-lux outdoor music venue coming to Colorado Springs. The highly anticipated music haven owned by live entertainment and hospitality company formally Notes Live, Inc. dba Venu Holding Corporation (“Venu”), is set for its Grand...

Continue reading

Tims China Announces First Quarter 2024 Financial Results

Resilient Total Revenues Increased 3.1% Year over Year for the First Quarter 2024 System Sales Increased 7.1% Year-over-Year for the First Quarter 2024 Continuous Margin Improvement with Seven Consecutive Positive Quarterly Adjusted Store EBITDA 20.3 Million Registered Loyalty Club Members at Quarter-End,Representing 63.6% Year-over-Year Growth SHANGHAI and NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) — TH International Limited (Nasdaq: THCH), the exclusive operator of Tim Hortons coffee shops and Popeyes restaurants in China (“Tims China” or the “Company”) today announced its unaudited financial results for the first quarter 2024. FIRST QUARTER 2024 HIGHLIGHTS Total revenues reached RMB346.8 million (USD48.0 million), representing a 3.1% increase from the same quarter of 2023. System sales1 reached RMB363.5 million (USD50.3 million),...

Continue reading

Fusion Fuel Green Hosts First Quarter 2024 Investor Update

SABUGO, Portugal, June 05, 2024 (GLOBE NEWSWIRE) — Fusion Fuel Green plc (NASDAQ: HTOO) (“Fusion Fuel”), an emerging leader in the green hydrogen sector, today announced financial results for the first quarter ended March 31, 2024. The quarterly shareholder letter is available at https://ir.fusion-fuel.eu/financials-filings/earnings-releases First Quarter 2024 Highlights Received notification of IPCEI approval from European Commission for 630 MW HEVO-Portugal Project Raised ~€6 million from at-the-market program to strengthen capital position Awarded €1.015 million grant from European Commission as part of H2tALENT consortium Received provisional grant approval for 25 MW HEVO-Aveiro green hydrogen project Convened EGM to secure shareholder approval allowing the Company to allot securities above 20% annual cap Subsequent...

Continue reading

Conditions of availability of information and documents related to the General Meeting of June 26, 2024

  Conditions of availability of information and documents related to the General Meeting of June 26, 2024 Paris, June 5, 2024 – The General Meeting of the Company will be held on first notice on Wednesday, June 26th, 2024, at 3 p.m. (Paris time), at l’Espace 73 – 73, rue d’Anjou, 75008 Paris, France. The notice of meeting, including the agenda and the text of the draft resolutions, was published at the French official legal announcement publication (BALO) on May 17th, 2024, Bulletin 60, under number 2401823. The convening notice will be published at the BALO and in a French Journal d’annonces légales, on Monday, June 10th, 2024. The participation and voting conditions at this meeting are included in these two notices. Information and documents relating to the General Meeting required under article R. 225-83 of the French commercial...

Continue reading

Vantiva – May 2024 – Information concerning the total number of voting rights and shares

June 5, 2024 Vantiva: Information concerning the total number of voting rights and shares, provided pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers Vantiva Shares(ISIN Code FR0013505062) Date Number of Outstanding Shares Number of Voting Rights May 31, 2024   490,143,003     Number of Theoretical Voting Rights(1): 490,143,003     Number of Voting Rights Exercisable at Shareholders’ meeting(2): 490,143,003   (1)    Calculated, pursuant to Article 223-11 of the General Regulations of the Autorité des Marchés Financiers, based on the total number of outstanding shares to which voting rights are attached, including shares with suspended voting rights. (2)    Excluding shares with suspended voting rights. *                ** About Vantiva www.vantiva.com...

Continue reading

UP Fintech Holding Limited Reports Unaudited First Quarter 2024 Financial Results

SINGAPORE, June 05, 2024 (GLOBE NEWSWIRE) — UP Fintech Holding Limited (NASDAQ: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced its unaudited financial results for the first quarter ended March 31, 2024. Mr. Wu Tianhua, Chairman and CEO of UP Fintech stated: “Market backdrop was more active in the first quarter, total revenue in the first quarter was US$78.9 million, representing a 12.8% increase sequentially and 19.0% increase compared to the same quarter last year. Benefiting from our brand strength and R&D capabilities, both GAAP and non-GAAP net income experienced significant growth. GAAP net income attributable to UP Fintech was US$12.3 million this quarter, compared to a net loss of US$1.8 million in the prior quarter and represent an increase of 54.8%...

Continue reading

VIS and NXP to Establish a Joint Venture to Build and Operate a 300mm Fab

HSINCHU, Taiwan and EINDHOVEN, The Netherlands, June 05, 2024 (GLOBE NEWSWIRE) — Vanguard International Semiconductor Corporation (“VIS”, TPEx 5347) and NXP Semiconductors N.V. (“NXP”, NASDAQ: NXPI) today announce the plan to create a manufacturing joint-venture VisionPower Semiconductor Manufacturing Company Pte Ltd (“VSMC”) which will build a new 300mm semiconductor wafer manufacturing facility in Singapore. The joint-venture fab will support 130nm to 40nm mixed-signal, power management and analog products, targeting the automotive, industrial, consumer and mobile end markets. The underlying process technologies are planned to be licensed and transferred to the joint venture from TSMC. The joint venture will begin construction of the initial phase of the wafer fab in the second half of 2024, pending receipt of all required regulatory...

Continue reading

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from six poster presentations at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy. The clinical poster presentations highlight the continued potent antiviral activity of ALG-000184 for chronic hepatitis B (CHB) in both HBeAg-positive and HBeAg-negative subjects. Data from ≤72 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated sustained HBV DNA suppression (

Continue reading

Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatment Of the patients who have stopped all therapy, six still have undetectable levels of HBsAg and HBV DNA, with two of these patients reaching 12 weeks off all therapy All six patients have seroconverted and have high titers of anti-HBsAg antibodies These new Phase 2a data were presented at the European Association for the Study of the Liver (EASL) Congress 2024 WARMINSTER, Pa., June 05, 2024 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...

Continue reading

Financing facility update

5 June 2024 ICG Enterprise Trust extends €240m revolving credit facility to 2028 ICG Enterprise Trust plc (‘ICGT’) is pleased to announce that it has extended the maturity of its €240m revolving credit facility (‘RCF’) by one year, from 30 May 2027 to 29 May 2028. There are no changes to any other key terms in the agreement as announced on 1 June 2023. At 31 May 2024, ICGT had total available liquidity of £166m (31 January 2024: £196m). This is comprised of £9m cash and £157m undrawn RCF. As of the same date, £59m was drawn on the RCF. Enquiries Analyst / Investor enquiries                                                                                                 Chris Hunt, Head of Shareholder Relations                 +44 (0) 20 3545 2000 Media                                                                                                               ...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.